TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03877471

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Cell therapy
Description: Ovary injection with MSC-like cells through transvaginal ultrasound,3 injection points for each ovary.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Cell therapy
Description: Ovary injection with MSC-like cells through transvaginal ultrasound,3 injection points for each ovary.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Cell therapy
Description: Ovary injection with MSC-like cells through transvaginal ultrasound,3 injection points for each ovary.
Study: NCT01174316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoVPAP™
Description: Automatically titrated non-invasive ventilator, with target gross alveolar ventilation, end expiratory positive pressure, and back up respiratory rate determined by the clinician based on height and weight. The NIV must be used for as many hours as possible over the 24 hour period but breaks for meals, physiotherapy and bathroom are allowed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VPAPIIIST-A™
Description: Standard non-invasive ventilator, with inspiratory and expiratory positive pressure determined by the healthcare professional. The NIV must be used for as many hours as possible over the 24 hour period but breaks for meals, physiotherapy and bathroom are allowed.
Study: NCT04181632

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Buzzy Bee with Ice pack
Description: Buzzy uses natural pain relief to block needle pain for blood draws and shots. This intervention will be used with an ice pack.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Buzzy Bee without Ice pack
Description: Buzzy uses natural pain relief to block needle pain for blood draws and shots. This intervention will be used without an ice pack.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shot Blocker
Description: Shot Blocker is a device that instantly alleviates the pain and anxiety of needle injections when pressed firmly against the skin at the injection site.
Study: NCT04159948

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate drink
Description: This is a commercially available pre-op carbohydrate drink used in enhanced recovery programmes.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate drink
Description: This is a commercially available pre-op carbohydrate drink used in enhanced recovery programmes.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate drink
Description: This is a commercially available pre-op carbohydrate drink used in enhanced recovery programmes.
Study: NCT01473719

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: motivational intervention
Description: 7-session individual motivationally-based intervention
Study: NCT01518335

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma injection
Description: 50ml of blood drawn into a 60cc with 10cc of anticoagulant is processed using MAGELLAN® Autologous Platelet (Arteriocyte Medical Systems, Cleveland Ohio)to separate out approximately 3-6 cc of platelet rich plasma, which is mixed with 1 cc of 1 % Lidocaine (xylocaine) and 1 cc of 0.25 % Marcaine (bupivacaine) and injected into the site of injury under USG guidance.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo/Standard of Care
Description: 50ml of blood is drawn into a 60cc with 10cc of anticoagulant and is then discarded. 4 cc of saline solution is mixed with 1 cc of 1 % Lidocaine (xylocaine) and 1 cc of 0.25 % Marcaine (bupivacaine) and injected into the site of injury under USG guidance.
Study: NCT01473719

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: health education
Description: 7 individual sessions focusing on health education
Study: NCT04469218

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SafeBreak Vascular
Description: SafeBreak Vascular is a breakaway connector that screws into peripheral IV lines using luer connectors on each end. The device is designed to separate when a harmful force is placed on an IV line. Upon separation, valves on each side of the device close. On the patient side of the device, the valve closes to prevent the loss of blood and on the IV pump side of the device, the valve closes to stop the flow of medication. The valve closing on the IV pump side of the line causes the pump's occlusion alarm to sound and notify nurses that the IV needs attention. The nurse is able to throw away the separated SafeBreak Vascular, install a new SafeBreak, and restart the patient's infusion without the negative cascade of events that can occur when a peripheral IV fails.
Study: NCT00832884

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lacosamide
Description: 0.7 mg/kg (up to maximum of 50 mg) x 5 subjects x 30 minutes; 1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 30 minutes; 2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 30 minutes; 2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 30 minutes.~0.7 mg/kg (up to a maximum of 50 mg) x 5 subjects x 15 minutes; 1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 15 minutes; 2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 15 minutes; 2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 15 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lacosamide
Description: 0.7 mg/kg (up to maximum of 50 mg) x 5 subjects x 30 minutes; 1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 30 minutes; 2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 30 minutes; 2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 30 minutes.~0.7 mg/kg (up to a maximum of 50 mg) x 5 subjects x 15 minutes; 1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 15 minutes; 2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 15 minutes; 2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 15 minutes
Study: NCT06747026

Intervention type: DRUG
Intervention: initial Sequential iRT
Description: For unresectable locally advanced NSCLC, definitive thoracic radiotherapy must have been administered as the initial treatment, with immunotherapy initiated within 90 days after RT.~For de novo metastatic NSCLC, radiotherapy targeting the primary lung tumor or metastatic lesions must have been administered as the initial treatment, with immunotherapy initiated within 90 days.

Intervention type: DRUG
Intervention: initial Concurrent iRT
Description: For unresectable locally advanced NSCLC, definitive thoracic radiotherapy must have been administered as the initial treatment, with immunotherapy concurrently with RT.~For de novo metastatic NSCLC, radiotherapy targeting the primary lung tumor or metastatic lesions must have been administered as the initial treatment, with immunotherapy concurrently with RT.
Study: NCT06747026

Intervention type: DRUG
Intervention: initial Concurrent iRT
Description: For unresectable locally advanced NSCLC, definitive thoracic radiotherapy must have been administered as the initial treatment, with immunotherapy concurrently with RT.~For de novo metastatic NSCLC, radiotherapy targeting the primary lung tumor or metastatic lesions must have been administered as the initial treatment, with immunotherapy concurrently with RT.
Study: NCT04546269

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fully-guided vs. conventionally guided implant placement
Description: Patients randomized to implant placement planned virtually based on a CBCT and a surface scan vs. implant placement based on a wax-up on gypsum casts
Study: NCT06747026

Intervention type: DRUG
Intervention: RT with maintenance of ICI
Description: For post-treatment progressive NSCLC, salvage radiotherapy performed during immunotherapy.
Study: NCT00770679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lipitor
Description: 80 mg everyday (QD) for 3 weeks
Study: NCT04546269

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fully-guided vs. conventionally guided implant placement
Description: Patients randomized to implant placement planned virtually based on a CBCT and a surface scan vs. implant placement based on a wax-up on gypsum casts
Study: NCT00470743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indomethacin
Study: NCT00966966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAM-531 and gemfibrozil
Description: 2 single doses of 5 mg SAM-531 (capsules) a daily dose of 1200 mg Gemfibrozil (one tablet of 600mg at approximately 8 a.m. and one tablet of 600 mg at approximately 6 p.m.) for 14 days
Study: NCT04590651

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Routine phacoemulsification cataract surgery using the Alcon Centurion® device.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery with extra anterior chamber angle aspiration
Description: Routine phacoemulsification cataract surgery using the Alcon Centurion® device. At the end of the case a one minute extra anterior chamber angle aspiration will be preformed after the removal of the viscoelastic agent.
Study: NCT02760381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBI + Acetic Acid (AA)
Description: Patients belonging to the Routine colonoscopy Cohort will receive NBI + Acetic Acid (AA) chromoendoscopy for optical predictions of colonic polyps.
Study: NCT06747026

Intervention type: DRUG
Intervention: RT after discontinuation of ICI
Description: For post-treatment progressive NSCLC, salvage radiotherapy performed during within 90 days after the cessation of immunotherapy.
Study: NCT02485158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: This is a within-subjects, double-blind, placebo controlled design. We administered oral THC to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: This is a within-subjects, double-blind, placebo controlled design. We administered oral THC to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMP
Description: This is a within-subjects, double-blind, placebo controlled design. We administered AMP to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMP
Description: This is a within-subjects, double-blind, placebo controlled design. We administered AMP to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
Study: NCT00839501

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium
Description: 40 mEq twice daily in pill form during the first 3-day inpatient visit, followed by 40 mEq twice daily in liquid form during the first 18-week treatment period, as is randomly scheduled, and continued during the second 18-week treatment period as long as there are no limiting side effects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: 250 mg twice daily, orally, during the second 3-day inpatient visit and during the second 18-week treatment period, as is randomly scheduled
Study: NCT01356225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Description: 30 mg Intranasal (2 x 100 uL of a 15% solution), single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IN placebo
Study: NCT02266810

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROPEL Mini Sinus Implant.
Description: Placement of sinus implant following frontal sinus surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus Surgery alone
Description: Sinus surgery only, without implant placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus Surgery alone
Description: Sinus surgery only, without implant placement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Propel Nova Sinus Implant
Description: Placement of sinus implant following frontal sinus surgery
Study: NCT00404079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucosamine sulphate
Description: Oral intake of 1500 mg glucosamine sulfate(from Pharma Nord) daily for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral intake of 3 placebo capsules (similiar looking to the glucosamine sulfate capsules)daily for 6 months
Study: NCT03678116

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill (placebo)
Description: Taken orally in capsule form

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine (plus Teacrine and Cayenne)
Description: Taken orally in capsule form

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine (plus Teacrine)
Description: Taken orally in capsule form
Study: NCT06135831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional olive paste
Description: Homogenised olive pastes, enriched with mountain tea, were supplied by two ac-credited Greek olive oil and olive products companies, Arcadian Taste and GAEA. The fortified olive pastes, contained 7.5 g of extra virgin olive oil, 3.75 g of salt, 3.75 g of grated oregano, 3.75 g of grated pepper, 7.5 g of grated garlic, 6.25 g of orange juice, 65 g of Kala-mon olives without seeds and 3 g of mountain tea and weighted 100 gr per portion size, as well.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calciovitmag (CDCaMg)
Description: Vitamin C (1000 mg), vitamin D3 (500 mg), Calcium (Ca) (500 mg ) and Magnesium (Mg) (300 mg)/day
Study: NCT01052779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: IV Ferumoxytol
Study: NCT06135831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phosporovitmag (PDCaMg)
Description: Bisphosphonates (150 mg), vitamin D3 (500 mg), Ca (500 mg ) and Mg (300 mg)/daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Vitamin D3 (500 mg), Calcium (500 mg) and Magnesium (300 mg)/daily
Study: NCT02648425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASLAN001
Description: ASLAN001 400mg BID daily; ASLAN001 500mg BID daily; or ASLAN001 300mg BID daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASLAN001
Description: ASLAN001 400mg BID daily; ASLAN001 500mg BID daily; or ASLAN001 300mg BID daily
Study: NCT01052779

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Sucrose
Description: IV Iron Sucrose
Study: NCT02648425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin + capecitabine
Description: Cisplatin 80 mg/m2 IV infusion and capecitabine 1,000 mg/m2 orally BID for 14 days every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin + 5-fluorouracil (or+ Leucovorin)
Description: Cisplatin 80 mg/m2 IV infusion and 5-fluorouracil 800 mg/m2/day IV infusion for 5 days every 3 weeks;~Or~Cisplatin 35 mg/m2 24-hour infusion for day 1 and day 8, 5-fluorouracil 2,000 mg/m2 and Leucovorin 300mg/m2 24-hour infusion for day 1, day 8 and day 15 every 4 weeks.
Study: NCT01723670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074 1x
Description: oral tablet, 1x, once a day for 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074 2x
Description: oral tablet, 2x, once a day for 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet,once a day for 24 months
Study: NCT00624546

Intervention type: DRUG
Intervention: Prevacid Solutabs
Description: BID Prevacid Solutabs

Intervention type: PROCEDURE
Intervention: Antireflux surgery
Description: Lap Nissen
Study: NCT03433261

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: Eat a ketogenic diet (low carbohydrate, high fat diet) for 72 hrs prior to the experiment and consume a dietary ketone supplement 60 minutes before the experiment.
Study: NCT03452306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformine
Description: First aIntervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fasting condition

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage® Long
Description: Second Intervention Period:~Single administered dose of Glucophage® (750 mg tablet extended-release) in a fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Third Intervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage® Long
Description: Fourth Intervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition
Study: NCT01506362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-7040
Description: BL-7040 is an orally available new chemical entity for the treatment of IBD. BL-7040 is a synthetic oligonucleotide with dual activity on both the nervous and immune systems.~Study duration can last up to 8 weeks, including up to 9 days in the screening period, up to 5 weeks of treatment with BL-7040, and up to 2 weeks for follow up.~BL-7040 12 mg QD for 19-21 days followed by BL-7040 40 mg QD for 14 days.
Study: NCT04408287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WebEx Physical Activity Program
Description: The program will be delivered twice-weekly through 45-minute sessions over 6 weeks. An experienced fitness instructor with lived experience and a graduate student from the Department of Health and Rehabilitation Sciences, will lead a class of 4-6 participants. The sessions will be comprised of a 10-minute warm-up phase, a 25-minute aerobic phase and a 10-minute cool-down phase that will incorporate upper-extremity flexibility exercises and mindfulness meditation. Over the duration the instructor will be sensitive to varying levels of function and fitness and will structure the classes to enable a slow progression of intensity. Individual semi-structured interviews will be completed over the WebEx platform to garner feedback and improve study programming for future implementation of a health care service at Parkwood Institute Outpatient Clinic.
Study: NCT05507047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enamel Matrix Protein
Description: Enamel matrix derivated is used with transcrestal sinus lifting treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enamel Matrix Protein
Description: Enamel matrix derivated is used with transcrestal sinus lifting treatment
Study: NCT02485158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALC
Description: This is a within-subjects, double-blind, placebo controlled design. We administered alcohol to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALC
Description: This is a within-subjects, double-blind, placebo controlled design. We administered alcohol to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules
Description: This is a within-subjects, double-blind, placebo controlled design. We administered size 00 gelatin capsules containing dextrose to healthy volunteers as a control for when they received either amphetamine or THC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules
Description: This is a within-subjects, double-blind, placebo controlled design. We administered size 00 gelatin capsules containing dextrose to healthy volunteers as a control for when they received either amphetamine or THC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo beverage
Description: This is a within-subjects, double-blind, placebo controlled design. We administered a drink containing cranberry juice plus 1% alcohol added as a taste mask.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo beverage
Description: This is a within-subjects, double-blind, placebo controlled design. We administered a drink containing cranberry juice plus 1% alcohol added as a taste mask.
Study: NCT00005087

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01398202

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3
Description: 20 micrograms per day for 10 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 25-hydroxyvitamin D3
Description: 7 microgram/day for 10 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 25-hydroxyvitamin D (20 microgram/day)
Description: 20 microgramday for 10 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 ug vitamin D3/25-hydroxyvitamin D3/day for 10 weeks
Study: NCT00692315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylcobalamin (methylB12)
Description: 75 ug/Kg methylB12 every 3 days by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylcobalamin (methylB12)
Description: 75 ug/Kg methylB12 every 3 days by subcutaneous injection
Study: NCT00502593

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic Influenza Vaccine (GSK1562902A)
Description: 2 doses, intramuscular injection on Days 0 and 21, 3 different formulations are tested.
Study: NCT02247076

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Grazing
Study: NCT00502593

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic Influenza Vaccine (GSK1562902A)
Description: 2 doses, intramuscular injection on Days 0 and 21, 3 different formulations are tested.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic Influenza Vaccine (GSK1562902A)
Description: 2 doses, intramuscular injection on Days 0 and 21, 3 different formulations are tested.
Study: NCT01349088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Patients will receive capecitabine at 2000 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motesanib
Description: Patient will receive motesanib at 100mg or 125mg once daily dependent on outcome of Phase I, which will involve the first 3-6 patients.
Study: NCT01442454

Intervention type: OTHER
Intervention: chronic pancreatitis
Description: No intervention, subjects followed through surgery
Study: NCT02247076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted feeding (early eating)